Cendakimab

Summary

Cendakimab (CHEMBL4297864) is a phase-3 clinical-stage antibody; indicated across 2 conditions including eosinophilic esophagitis and asthma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297864
Name	Cendakimab
Type	Antibody
Max phase	3

Also known as: Abt-308, ABT-308, CC-93538, Cendakimab, RPC-4046, CENDAKIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eosinophilic esophagitis	3	MONDO:0005361	EFO:0004232
asthma	1	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	6
PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04753697	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935	PHASE3	COMPLETED	Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT05214768	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
NCT04800315	PHASE2	COMPLETED	A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
NCT00986037	PHASE1	COMPLETED	Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma
NCT04096105	PHASE1	COMPLETED	Japanese Pharmacokinetic Bridging Study for CC-93538
NCT04373187	PHASE1	COMPLETED	Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects
NCT05175352	PHASE1	COMPLETED	A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
NCT05337345	PHASE1	COMPLETED	A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
NCT05638282	PHASE1	COMPLETED	A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).